Archive

HIGHLIGHTS

 
LSP’s portfolio company Xeltis raises a substatial new round
Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces that its portfolio company Xeltis has raised a substantial new round. The clinical-[...]
 
LSP portfolio company Nouscom raises € 42m Series B round
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba[...]
 
Smith & Nephew acquires tissue regeneration technology for shoulder repair
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical[...]
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
LSP NEWS
LSP's portfolio company Affimed described
 
Is a cure for cancer finally within reach?
To read the full article click here
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat
 
LSP COMPANY NEWS
LSP Partner Clemens van Blitterswijk gives a Tedx on the future of regenerative medicine
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]

2017


argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p [...]
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hemat...
Workshop to be held on Monday, December 11th at 12:00 pm EST Breda, the Netherlands / Ghent, Belgium, December 11, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]
Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated; 3-month ORR compares favorably to historical ORR of pembrolizumab alone Additional preclinical data presented on BCMA-targe [...]
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo [...]
Is a cure for cancer finally within reach?
To read the full article click here [...]


2017
2016
2015
2014
2013
2012
back to news overview

Archive

HIGHLIGHTS

 
LSP’s portfolio company Xeltis raises a substatial new round
Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces that its portfolio company Xeltis has raised a substantial new round. The clinical-[...]
 
LSP portfolio company Nouscom raises € 42m Series B round
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba[...]
 
Smith & Nephew acquires tissue regeneration technology for shoulder repair
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical[...]
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
LSP NEWS
LSP's portfolio company Affimed described
 
Is a cure for cancer finally within reach?
To read the full article click here
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat
 
LSP COMPANY NEWS
LSP Partner Clemens van Blitterswijk gives a Tedx on the future of regenerative medicine
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]

$smarty.now|date_format:"%Y"


argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p [...]
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hem...
Workshop to be held on Monday, December 11th at 12:00 pm EST Breda, the Netherlands / Ghent, Belgium, December 11, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]
Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated; 3-month ORR compares favorably to historical ORR of pembrolizumab alone Additional preclinical data presented on BCMA-targe [...]
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo [...]
Is a cure for cancer finally within reach?
To read the full article click here [...]


2017
2016
2015
2014
2013
2012
back to news overview